|
|
 |
|
Viewing report
|
|
|
|
Drugs of Tomorrow 2000: Allergic Rhinitis - New Drug Classes, Towards Total Disease Management
Datamonitor, Jan 2001
A global increasing in the prevalence of allergic rhinitis, coupled with increasing disease awareness and a growing drug treated population, has driven the need for more innovative therapies. The market for drugs, such as the antihistamines, that provide symptomatic relief is mature. Therefore, if innovative products are to gain significant market share, they will need to be orally administered, effective when dosed once a day and very safe. Drugs of Tomorrow 2000: Allergic Rhinitis provides an in-depth analysis of allergic rhinitis pipeline products and forecasts their performance to 2007. The report provides comprehensive coverage of all phase II and phase III treatments indicated for allergic rhinitis and assesses the current and future commercial attractiveness of the drug classes.
Customers who bought this item also bought
Commercial and Pipeline Insight: Allergic Rhinitis
Allergic Rhinitis Opinion Leader Forum, 2002
Strategic Perspectives: Allergic Rhinitis - Impact of a blockbuster going bust
Market Dynamics 2000: Allergic Rhinitis: Effects of Major Patent Expiries On An Expanding Market
Br Malls Participacoes Sa
Br. Holdings Corporation
Pipeline Insight: Asthma, Copd and Allergic Rhinitis - The Needs of Severe Patients Must be Addressed
The Asthma, COPD & Allergic Rhinitis Market Outlook to 2011
Treatment Algorithms 2001: Allergic Rhinitis - Unlocking the Real Patient Potential
Pipeline Insight: Asthma, COPD and Allergic Rhinitis - Weak Late Stage Pipeline Leaves Innovation to Phase I/II Candidates
Commercial and Stakeholder Perspectives: Allergic Rhinitis - Is There Life After Claritin?
Pipeline Insight: Asthma/COPD/Allergic Rhinitis - As Patents Expire, Novel Combinations Inspire
|
|
|
|
